Medications
Resources
Basic InformationLatest News
COVID Drug Remdesivir Could Cost Up to $3,120 Per Patient, Maker SaysHigh Costs Lead Millions of Americans to Shop Abroad for Rx DrugsFDA Pulls Emergency Approval of Hydroxychloroquine for COVID-19How Ritalin Works in the BrainFDA Pulls Heartburn Drug Zantac From MarketAllergy Med Singulair to Get 'Black Box' Warning Over Psych Side Effects: FDAU.S. Drug Prices Have Risen Three Times Faster Than InflationUse Pot? It Can Interact With Your Meds in Harmful WaysToo Many Antibiotics, Opioids Given to Dental Patients in the ERBrand-Name Rx Rise After Docs Get Drug Company Perks: StudyAs Prices Rise for Parkinson's, Alzheimer's Meds, Patients Go WithoutPrice Hikes Have Patients Turning to Craigslist for Insulin, Asthma InhalersAI May Help Guide Patients to Most Effective Antidepressant1 in 4 Gets Unneeded Antibiotics at Children's HospitalsStudy Finds 'No Clear Rationale' for 45% of Antibiotic PrescriptionsAre Antibiotics a Recipe for Obesity in Childhood?Do You Take Warfarin? Time of Day Might Not MatterNew Drugs Getting FDA's Blessing Faster, but Is That a Good Thing?Health Tip: Acetaminophen SafetyTwo More Heartburn Meds Recalled Due to Possible CarcinogenMany Drugstores Misinform on Disposal of Unused MedsHealth Tip: How to Remember to Take Your MedicationsFDA to Allow States to Import Prescription Drugs From Other CountriesOver 40% of Antibiotics Could Be 'Inappropriately' PrescribedFDA Testing Levels of Carcinogen in Diabetes Drug MetforminTaking Several Prescription Drugs May Trigger Serious Side EffectsPenicillin Allergy Less Common Than Thought: StudyMany Older Americans Misuse Antibiotics: PollAntibiotics Not Recommended for Most Toothaches, New Guideline SaysHealth Tip: Taking Anti-Inflammatory DrugsMany Common Meds Could Alter Your MicrobiomeWhen Meds Are Free, Patients Take Them More OftenMaker Halts Distribution of Generic Zantac Due to Possible CarcinogenKids Often Prescribed Drugs 'Off-Label,' Raising ConcernsHeartburn Drug Zantac May Contain Small Amounts of Known Carcinogen, FDA SaysHealth Tip: Take Over-the-Counter Medication WiselyA Prescription for Medicating Your Child SafelyHealth Tip: Taking Dietary SupplementsTrump Administration Announces Plan to Allow Cheaper Drug Imports From CanadaAre Too Many Kids Prescribed Antihistamines?Some Meds and Driving a Dangerous DuoHealth Tip: Giving Medicine Safely to ChildrenHigher Cost of New Cholesterol Drugs Putting Patients at Risk: StudyMany Americans Take Antibiotics Without a PrescriptionHealth Tip: Packing Prescriptions for Travel
Links
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

Higher Cost of New Cholesterol Drugs Putting Patients at Risk: Study

HealthDay News
by By Dennis ThompsonHealthDay Reporter
Updated: Jul 23rd 2019

new article illustration

TUESDAY, July 23, 2019 (HealthDay News) -- Heart attacks, strokes and other heart problems are more likely in high-risk patients denied access to cutting-edge cholesterol-busting drugs called PCSK9 inhibitors, a new study reports.

Patients are 16% more likely to have a heart-related health crisis if their PCSK9 prescription is rejected than if it is covered and filled for a year, according to researchers.

Patients who have a prescription but don't fill it -- probably because they can't afford the copay -- have a 21% greater risk of a heart-related emergency, the researchers added.

"We should be a little up in arms that we have the tools to help people, and we aren't helping them," said study co-author Katherine Wilemon, founder and CEO of the FH Foundation, a research and advocacy group for patients with familial hypercholesterolemia, high cholesterol related to their genetics.

PCSK9 inhibitors entered the U.S. market in 2015, but remain costly compared with first-line statin therapy, researchers said. The new drugs work by boosting the liver's ability to remove excess cholesterol from the bloodstream.

The drugs cost about $14,000 a year during the time covered by this study, 2015 to 2017, researchers said. Manufacturers last year announced price cuts to the two leading PCSK9 inhibitors -- Praluent (alirocumab) and Repatha (evolocumab) -- but the cost is still $4,500 to $8,000 a year.

For this study, researchers reviewed medical records and pharmacy claims of about 139,000 high-risk adults after PCSK9 inhibitors became available in 2015. On average, patients were tracked for about a year after their prescription date.

Patients were considered at high risk if they had familial hypercholesterolemia or had suffered heart problems related to clogged arteries.

"This group was at extremely high risk in total," said lead researcher Kelly Myers, chief technology officer for the FH Foundation. "The annual rate of cardiovascular events in this group was about 3.5%. The annual rate for the entire adult U.S. population is less than half a percent."

The researchers specifically looked at access to the new cholesterol drugs, and whether it influenced patients' risk for heart-related health events such as heart attacks, unstable angina, angioplasty, coronary bypass surgery, cardiac arrest, and heart disease or stroke caused by congested arteries.

Insurance companies rejected about two-thirds of PCSK9 prescriptions among high-risk patients, researchers found.

Even after the 2018 price cuts, rejection rates have remained high, Myers said.

"We haven't seen a lot of evidence in the data that there's been a compelling change yet," he said. "There's general improvement, but over 50% of individuals in a lot of plans are still being rejected therapy."

In addition, about 15% of people with an approved prescription didn't have it filled, probably because they couldn't afford it, Myers added.

Two-thirds of patients who didn't fill their PCSK9 inhibitor prescription are on Medicare, which doesn't allow for copay assistance, Myers said. Their average copay for the drugs is $200 a month, compared to $100 month for people with private prescription insurance.

"They're probably abandoning their therapy because of extremely high copay costs," Myers said.

Lack of access to these drugs had an immediate impact on their risk of heart attack, stroke and other heart problems, researchers found.

"People whose cholesterol-lowering drug prescriptions are rejected or abandoned are more likely to have heart events than those whose prescriptions are covered," said Dr. Donald Lloyd-Jones, chairman of preventive medicine at Northwestern University Feinberg School of Medicine in Chicago and a American Heart Association (AHA) spokesman.

The researchers also found that a prescription was more likely to be rejected if a patient is female, black or Hispanic.

"The study clearly shows how disparities in access to PCSK9 inhibitor prescriptions affect cardiovascular outcomes and the need to improve health equity," Lloyd-Jones added. "So as we continue to make inroads to prevent and treat heart disease -- the world's leading killer -- we must capitalize on data from this study and others that quantify ways we can make a difference."

The AHA changed its cholesterol guidelines in 2018 to promote the use of PCSK9 inhibitors among high-risk people who are already taking the largest dose of statins they can tolerate.

The findings were published July 23 in the journal Circulation: Cardiovascular Quality and Outcomes.

More information

The FH Foundation has more about insurance coverage for cholesterol drugs.




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net